Epoch (epoetin beta biosimilar) / Roche - LARVOL DELTA

R-mini-CHOP preserves efficacy and limits toxicity for patients ≥ 80 years old with DLBCL (ASH 2025) - "A total of 651 (46.8%) pts received 1L R-CHOP/R-EPOCH, 395 (28.4%) received 1L R-mini-CHOP, and 292(21.0%) received 1L Other Frail Regimens (mostly commonly including R-CVP, single agent R and R-bendamustine)... We present one of the largest real-world datasets of pts with DLBCL ≥ 80. Utilization of R-mini-CHOP resulted in comparable outcomes to more intensive regimens, with lower rates ofdiscontinuation due to toxicity. However, use of further intensity-modified frail regimens resulted inworse outcomes compared to R-mini-CHOP, despite similar baseline age and CCI scores."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Genetic Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP (ASH 2025) - "These data may helpinform clinical decision-making and provide a basis for designing future trials targeting this population,where R-miniCHOP could serve as a comparator arm. Funding: NU21-03-00411, U01 CA195568."

Clinical • B Cell Lymphoma • Heart Failure • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study (ASH 2025) - P=N/A | "In this large international analysis of patients with newly diagnosed THRLBCLcontemporaneously treated, we observed similar survival rates compared to DLBCL NOS treated with R-CHOP and intensive regimens. ECOG PS and the presence of B symptoms were independent factorsassociated with survival."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Rare Diseases • T Cell Histiocyte Rich Large B Cell Lymphoma

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis (ASH 2025) - "In patients that proceeded to ASCT, relapses occurred in 10pts (40%) with a 3 yr PFS and OS 56% and 83%, respectively.CAR-T was used as 2L in 20 pts (14%)- most commonly either axi-cel (N =7) or liso-cel (N = 8)...Other 2L treatments included pembrolizumab (N =3), brentuximabvedotin (BV) + nivolumab (N= 4) or single agent BV (N=2)... We report the largest cohort of pts with RR PMBCL treated in the rituximab era and thelargest number of PMBCL pts treated with 2L CAR-T. This is the first analysis, to our knowledge, to show astatistically significant benefit in PFS, ORR and CR rate of CAR-T compared to platinum salvage followedby HDT/ASCT as 2L treatment in a study of exclusively RR PMBCL pts. Our dataset was largely (93%)compromised of pts with primary refractory or early relapsing disease and provides support for usingCAR-T as 2L treatment in this high-risk subset of RR PMBCL patients."

Retrospective data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Transplantation

Anatomical localization-based analysis of de novo secondary cns lymphoma (ASH 2025) - "Among patients with available data, 14 (43.8%) were positivefor MYC rearrangement, 13 (54.2%) for BCL2 rearrangement, and 10 (45.5%) for BCL6 rearrangement.First-line regimens received by patients included MR-CHOP (n=18, 52.9%), DA-R-EPOCH (n=5, 14.7%),combined CODOX-M/IVAC (n=4, 11.7%), R-CHOP with intrathecal methotrexate (n=3, 8.8%), miscellaneoustherapies (n=3, 8.8%), and MRT (n=1, 2.9%)...DN-SCNSL can be anatomically classified into two subtypes: LM-DN-SCNSL and P-DN-SCNSL. While aprognostic trend favoring the parenchymal subtype was observed, the difference did not achievestatistical significance, a finding likely attributable to the small cohort size. This classification may holdclinical utility for guiding risk stratification, and larger studies are needed to validate these findings andidentify the most optimal treatments for each subtype of DN-SCNSL."

B Cell Lymphoma • CNS Disorders • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Secondary Central Nervous System Lymphoma • BCL2 • BCL6

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis (ASH 2025) - "Introduction The ECHELON-2 trial for newly diagnosed CD30+ peripheral T-cell lymphomas (PTCL) demonstratedsuperior overall survival with brentuximab vedotin plus chemotherapy (BV-CHP) compared to CHOP.However, total enrollment was restricted to only 30% of patients with non-anaplastic large cell lymphoma(ALCL) histologies and was not powered to analyze survival benefits in this cohort...Adding to this uncertainty, CHOP plus etoposide (CHOEP)remains a standard regimen for many non-ALCL PTCL histologies for patients <60 years of age...ASCT forpatients in CR offered superior outcomes, supporting this strategy regardless of the frontline regimen,recognizing the limitations of non-randomized, retrospective analyses. Novel-CHOP regimensdemonstrated encouraging survival, and clinical trials should maintain priority over standard regimensfor patients with CD30+ (1-10%) PTCL-NOS and PTCL-TFH."

Retrospective data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma (ASH 2025) - "MethodsWe harmonized and pooled data from 6,941 patients with newly diagnosed systemic LBCL treated with R-CHOP-like regimens (R-CHOP, R-miniCHOP, DA-EPOCH-R, R-CHOEP, R-CHOP+X) with complete IPI datafrom three prospective cohorts: NiHiL (Czech Republic, n=4,590; 2010–2023), LEO (USA, n=1,789; 2015–2020), and MER (USA, n=562; 2010–2015)...These findings underscore the need for more individualized prognostic tools forLBCL patients. Funding: NU21-03-00411, P50 CA97274, U01 CA195568, Charles University Haematology-OncologyCooperatio Program."

Clinical • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CA724 • CA9

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States (ASH 2025) - "This is the first U.S.-based real-world analysis of Glofit-GemOx, including more U.S. pts than the STARGLOtrial, appear to demonstrate comparable response rates, potentially supporting its use as both bridgingand destination therapy. Notable toxicities, including CRS, were observed, with 2 possible treatment-related deaths, with plausible alternate non-treatment related causes. Favorable responses were seen inbridging therapy and high-risk subgroups (transformed, HGBCL) which were excluded in the STARGLOtrial."

Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Influenza • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Respiratory Diseases • CD20

Behavioral and Electrophysiological Arousal from Sleep with Intralaminar Thalamic Stimulation: Titration of Parameters for Epilepsy Therapy (AES 2025) - "These findings indicate that stimulation of the CL nucleus of the thalamus reliably elicited transient arousal from sleep across patients, as evidenced by reductions in delta and theta power and concurrent increased physiological and behavioral markers of arousal. These findings highlight the CL as a critical node in the regulation of human arousal and suggest its potential as a therapeutic target for neuromodulation of impaired consciousness in epilepsy and other disorders."

CNS Disorders • Epilepsy

Incidence of Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study (ASH 2023) - "16 patients received intrathecal (IT) chemotherapy (methotrexate and/or cytarabine) for CNS prophylaxis, 3 with R-CHOP and 13 with R-DA-EPOCH...The patient was treated with HD-MTX, temozolomide and rituximab for CNS relapse, and subsequently received multiple therapies for systemic disease including R-DHAP, R-ICE, and died 17 months after CNS relapse...CNS relapse was associated with poor survival despite aggressive treatment approaches. Novel approaches utilizing biological risk factors for CNS relapse, such as circulating tumor DNA, are needed to identify patients with CNS relapse."

Retrospective data • B Cell Lymphoma • Classical Hodgkin Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics (ASH 2024) - "For > 90% of pts, the RDI was ≥90% for all individual components except vincristine (78%). There were 2 dose interruptions of doxorubicin (AMI [n=1], and poor performance status [n=1]), and 5 interruptions of glofit, (infection [n=3], hepatotoxicity [n=1], and rash [n=1])...With these regimens, PMR at EOI does not necessarily represent treatment failure, and cfDNA may be useful to further investigate outcomes in this setting. CRR and preliminary PFS is promising compared to historical outcomes in pts with HR LBCL."

Clinical • FDG PET • P2 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Cardiomyopathy • Cardiovascular • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hepatology • Indolent Lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma (ASH 2023) - "Patients requiring early initiation of therapy for aggressive B-cell lymphoma represent a distinct population of patients with more aggressive clinical features and inferior outcomes. In patients with longer DTI, high grade subtypes had similar outcomes to DLBCL, NOS. Efforts should be made to include patients with anticipated short DTI in clinical trials and translational studies to fully capture the spectrum of patients with aggressive B-cell lymphoma."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6

Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium (ASH 2023) - "Patterns of care in Transformed FL are heterogeneous and vary greatly in intensity. These data confirm previous reports that age, early HT, and any systemic therapies prior to HT are negative prognostic indicators for OS. At HT elevated LDH, low hemoglobin, POD24 status, poor performance status, and HT to HGBCL were associated with poor outcomes following HT."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study (ASH 2023) - P=N/A | "The most common 1st line chemotherapy regimens overall were CHOP-based (N=506, 70%), including 60% receiving CHOP-like chemotherapy in both MER and LEO cohorts (CHOP [N=268, 37%], CHOEP [N=91, 13%] or EPOCH [N=75, 10%]), and 16% with CHOP-like in combination with novel agents in LEO cohort (BV+ [N=41, 9.3%], azacitidine+ [N=11, 2.5%], pralatrexate+ [N=10, 2.3%], lenalidomide+ [N=8, 1.9%]) (Table 1)...Outcomes continue to mature with longitudinal follow-up and ongoing accrual, which poise to shape benchmarks in the contemporary era. The lack of benefit of etoposide adding to CHOP induction and poor overall survival of non-ALCL subtypes underscores the unmet need of therapeutic breakthrough for non-ALCL frontline treatment, particularly through clinical trials with biomarker-guided approaches incorporating novel agents."

Clinical • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK

Cumulative Incidence, Predictors, and Outcomes of Transformation to Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Patients with Marginal Zone Lymphoma (ASH 2023) - "Twenty-six (81%) were treated with a systemic therapy, mainly CHOP-backbone therapy (R-CHOP n=13, CHOP n=4, R-EPOCH n=3, lenalidomide-R-CHOP n=1)... In this North American prospective cohort of mainly non-Hispanic White patients, we found a low cumulative incidence of HT in MZL of 2.9% and 4.5% at 5- and 10-year, which was consistent with the Finnish findings (Kalashnikov et al., 2023). At HT, age was associated with OS and there was a high response rate to CHOP-backbone therapies."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A pilot study using actigraphy to examine activity performance and its relationship with activity capacity in adults with facioscapulohumeral muscular dystrophy. (PubMed, J Neuromuscul Dis) - "Correlations were found between total MVPA and 10mw/r (ρ=-0.720, p = 0.006) and TUG-comfortable (ρ=-0.720, p = 0.006), and between maximum step count and several functional measures.ConclusionThis pilot study provides insights into activity performance and its relationship with capacity in a small cohort of adults with FSHD. Total MVPA and maximum step count appear most informative for evaluating activity performance; larger studies are needed to confirm findings and assess psychometric properties of these metrics."

Journal • Muscular Dystrophy

A long-necked early dinosaur from a newly discovered Upper Triassic basin in the Andes. (PubMed, Nature) - "Compared to its generally small and short-necked Carnian counterparts9,10, Huayracursor is larger and exhibits an incipient elongation of its cervical vertebrae, representing an intermediate condition for size and cervical elongation between known Carnian and Norian sauropodomorphs11. This discovery provides one of the oldest pieces of evidence of increased body mass and neck elongation in early Sauropodomorpha."

Journal

Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL: A Phase II Trial by the International Lymphoma Radiation Oncology Group (ASTRO 2025) - "ChI primarily consisted of R-CHOP (n=198, 82%) or R-EPOCH (n=19, 8%)... Results of this phase II study demonstrate high rates of local control with a lower dose of consolidation RT in a diverse population of patients with DLBCL/HGBL achieving a metabolic CR by post- ChI PET-CT. While guidelines currently recommend 30 Gy, this could be reduced to 20 Gy if high rates of local control are maintained with longer follow-up. A reduction in RT dose will decrease both acute and long-term toxicity."

P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Oncology

Clinical, Economic, and Humanistic Outcomes of First-Line High-Risk Large B-Cell Lymphoma: A Series of Systematic Literature Reviews (SOHO 2025) - "Older regimens, with robust long-term data highlight poor prognosis in double-expressor lymphoma and patients with DHL, while newer therapies, such as axi-cel (in trials) demonstrate potential for improved OS (12 m, 91%; 36 m, 81%) and progression-free survival (PFS; 12 m, 75%; 36 m, 75%). Novel combination regimens that incorporated additional agents, such as Pola-R-CHP + venetoclax and R-CHOP + azacitidine achieved higher response rates than standard therapies... Although available data indicate that approved treatments may be beneficial, the clinical burden in 1L high-risk LBCL remains considerable and has potential to impact costs. The literature underscores the need for more clinically effective treatments. Effective 1L therapies for high-risk LBCL could help reduce the need for subsequent treatments, ultimately improving patient outcomes while lowering overall healthcare costs."

Clinical • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Aggressive Presentation of Mediastinal Gray Zone Lymphoma as Pericardial Effusion (SOHO 2025) - "He was transitioned to salvage therapy with brentuximab vedotin and nivolumab... This case highlights the diagnostic and therapeutic complexity of MGZL, particularly when presenting as pericardial effusion. Clinicians should consider malignancy in young adults with atypical chest symptoms, and early multidisciplinary input is key to optimal management."

IO biomarker • B Cell Lymphoma • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • ALK • CD20 • FUT4 • IRF4 • PAX5 • PTPRC • TNFRSF8

Evaluating Sleep Architecture Variability in Older Adults with Cognitive Decline (WSS 2025) - "Important night-to-night variability was observed in all sleep architecture measures except %N2. These findings point to a first night effect and suggest multiple nights would be useful in evaluating patients with cognitive impairment in their home. Technical edits to the auto-staging most prominently impact stages N1 and REM, primarily during Night-1."

Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Sleep Disorder

Investigation of Factors that Impact the Accuracy of Auto-detected REM Sleep with Atonia (WSS 2025) - "Despite over-reporting auto-staged REM sleep in the MCI/AD group and under-reporting REM in the iRBD group, the distribution of cases with abnormal RSWA densities were similar before and after editing. Rules that rejected Chin-RSWA during periods with snoring or movement had the greatest impact on abnormal RSWA density distributions, reducing the number of presumed false-positive RSWA cases in the MCI/AD group while having no impact on abnormal Chin-RSWA or Amy-RSWA distributions in the iRBD group."

Alzheimer's Disease • Behavior Disorders • CNS Disorders • Cognitive Disorders • Dementia • Mental Retardation • Movement Disorders • Parkinson's Disease • Psychiatry • REM Sleep Behavior Disorder • Sleep Disorder

The fall of the old guard - evolving perceptions on the origin of disease in the Early Modern period (ECP 2025) - "While many of the theories developed in this period would be ultimately superseded in the following centuries, the willingness to question entrenched tradition and embrace experimentation laid the groundwork for modern medicine. As we enter into this new epoch of precision medicine, we too must not fall into the trap of clinging to the familiar at the expense of progress."

Navigating real-world challenges: A case study on federated learning in computational pathology. (PubMed, J Pathol Inform) - "Lastly, effective experiment management required IT expertise and strong familiarity with NVIDIA FLARE to enable orchestration, code management, parameter configuration, and logging. Our findings provide a practical perspective on implementing FL for CPATH, advocating for greater transparency in future research and the development of best practices and guidelines for implementing FL in real-world healthcare settings."

Journal • Real-world evidence • Melanoma • Oncology • Solid Tumor

Genome Survey and Evolutionary Analysis of Eight Lamprotula Species: SSR Profiling, Mitochondrial Characterization, and Population Dynamics Inference. (PubMed, DNA Res) - "Pairwise Sequentially Markovian Coalescent (PSMC) analysis revealed population bottlenecks over the past million years, with L. rochechouarti showing more significant population size fluctuations during the Pleistocene Glacial Epoch. In summary, this study provides comprehensive genomic insights into eight Lamprotula species, highlighting their high genomic complexity and evolutionary divergence, thereby establishing a crucial foundation for future conservation and genetic research efforts."

Journal